CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Raymond James & Associates

Raymond James & Associates raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,839 shares of the company’s stock after acquiring an additional 3,231 shares during the quarter. Raymond James & Associates’ holdings in CRISPR Therapeutics were worth $1,993,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CRSP. CWM LLC lifted its holdings in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares during the period. Tradewinds Capital Management LLC lifted its holdings in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares during the period. Headlands Technologies LLC acquired a new position in CRISPR Therapeutics in the third quarter valued at approximately $34,000. BluePath Capital Management LLC acquired a new position in CRISPR Therapeutics in the third quarter valued at approximately $37,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in CRISPR Therapeutics by 137.9% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,035 shares of the company’s stock valued at $48,000 after acquiring an additional 600 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, General Counsel James R. Kasinger sold 2,801 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $78.26, for a total value of $219,206.26. Following the transaction, the general counsel now owns 60,070 shares of the company’s stock, valued at approximately $4,701,078.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the transaction, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 114,410 shares of company stock valued at $7,984,677. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CRSP. Chardan Capital boosted their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Wells Fargo & Company boosted their price objective on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Mizuho boosted their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Barclays boosted their price objective on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $74.93.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $57.96 on Wednesday. The stock has a 50 day moving average price of $73.89 and a 200 day moving average price of $63.30. The stock has a market capitalization of $4.92 billion, a price-to-earnings ratio of -29.57 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. The business’s quarterly revenue was up 3253.3% on a year-over-year basis. During the same period last year, the firm posted ($1.41) EPS. On average, analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.